Tables S2. Best ligand RMSD relative to crystal structures following IFD with corresponding ROC AUC and adjusted logAUCs following virtual screening. The ligand used for the antagonist dataset was taranabant, while the ligand used for the agonist dataset was AM11542. RMSD values were calculated following optimal superimposition of the receptor transmembrane backbone. 
A) CB1-

G) CB1-AM11542 simulations mean values
Antagonist Dataset Agonist Dataset
Time ( 0 5.61 ± 0.13 54.8 ± 6.7 0.5 ± 1.9 2.98 ± 0.03 82.5 ± 1.5 21.1 ± 2.4 50 6.09 ± 1.56 50.9 ± 10.8 -0.5 ± 3.4 3.51 ± 0.59 73.5 ± 5.0 9.4 ± 4.1 100 4.61 ± 0.98 53.2 ± 5.0 -0.9 ± 2.2 3.43 ± 0.16 72.1 ± 0.8 9.4 ± 0.8 150 6.22 ± 0.75 68.1 ± 12.3 7.7 ± 6.7 3.35 ± 0.53 72.3 ± 2.9 11.4 ± 1.9 200 4.94 ± 0.60 47.1 ± 16.8 -1.4 ± 6.8 4.02 ± 0.65 68.1 ± 5.8 6.7 ± 3.7 250 6.98 ± 1.40 52.8 ± 7.4 -0.4 ± 2.2 5.05 ± 1.59 75.0 ± 8.2 12.6 ± 6.7 300 6.11 ± 0.46 63.4 ± 2.7 3.6 ± 2.3 3.37 ± 0.20 72.1 ± 3.0 10.7 ± 2.2 350 6.50 ± 0.31 50.6 ± 10.0 -1.3 ± 3.4 4.11 ± 0.39 75.0 ± 3.2 15.6 ± 4.4 400 4.69 ± 1.57
53.3 ± 4.6 -0.2 ± 0.7 4.99 ± 1.66 76.5 ± 6.2 14.8 ± 2.5 450 6.03 ± 1.50
46.7 ± 8.3 -1.9 ± 3.6 3.92 ± 0.49 73.0 ± 2.3 10.3 ± 2.1 500 6.58 ± 1.52
55.9 ± 6.1 2.0 ± 2.0 4.63 ± 1.64 70.3 ± 7.8 8.8 ± 4.3 550 5.38 ± 0.77 51.4 ± 13.6 -0.5 ± 4.2 4.01 ± 0.44 76.3 ± 3.7 16.5 ± 1.4 600 6.73 ± 0.53 55.6 ± 10.9 2.6 ± 5.3 4.52 ± 1.73 65.5 ± 7.7 7.5 ± 5.5 650 6.83 ± 0.27 57.6 ± 3.5 1.9 ± 2.5 4.00 ± 0.85 72.1 ± 2.9 14.7 ± 2.1 700 6.30 ± 0.32 53.1 ± 5.5 1.5 ± 0.6 4.69 ± 0.30 70.0 ± 6.4 10.2 ± 4.4 750 6.35 ± 0.51 59.5 ± 11.6 3.5 ± 6.0 5.52 ± 1.75 80.6 ± 1.3 19.4 ± 2.7 800 6.88 ± 0.12 52.8 ± 9.7 0.2 ± 4.1 3.44 ± 0.43 73.1 ± 6.8 16.1 ± 8.8 850 6.43 ± 0.12 43.1 ± 4.6 -4.4 ± 1.2 4.04 ± 0.67 74.6 ± 1.4 12.7 ± 3.7 900 5.95 ± 0.48 57.5 ± 12.9 3.7 ± 6.4 3.05 ± 0.44 72.1 ± 0.9 12.8 ± 2.3 950 8.10 ± 1.05 57.6 ± 13.2 4.1 ± 7.4 4.14 ± 0.39 75.5 ± 1.7 11.5 ± 2.1 1000 7.69 ± 1.32 51.2 ± 4.8 -0.7 ± 1.7 4.95 ± 1.14 66.5 ± 1.7 6.1 ± 1.2 Whole simulation 6.23 ± 1.26 54.1 ± 10.9 0.9 ± 4.9 4.08 ± 1.17 73.2 ± 6.1 12.3 ± 5.4 40.3 ± 5.8 -4.8 ± 1.9 77.8 ± 3.0 14.5 ± 3.0 100 46.5 ± 7.6 -3.2 ± 2.4 76.1 ± 5.7 14.7 ± 6.0 150 53.8 ± 6.1 -1.0 ± 2.2 71.6 ± 1.6 8.9 ± 1.2 200 46.6 ± 8.8 -2.9 ± 3.1 74.1 ± 3.9 10.9 ± 3.0 250 46.9 ± 8.5 -3.0 ± 3.1 72.9 ± 4.3 11.4 ± 3.2 300 47.3 ± 2.6 -3.1 ± 1.0 75.8 ± 3.5 13.4 ± 3.0 350
H) CB1*-taranabant simulations mean values
G) CB1-AM11542 simulations mean values
54.2 ± 6.8 0.0 ± 3.3 77.9 ± 0.3 14.7 ± 1.4 400 45.6 ± 7.4 -3.4 ± 2.4 75.7 ± 4.4 11.5 ± 4.7 450 59.2 ± 9.6 3.5 ± 5.6 78.5 ± 2.0 14.0 ± 1.9 500 51.9 ± 2.5 -0.4 ± 1.2 70.1 ± 4.4 7.5 ± 1.9 550 56.0 ± 8.2 1.8 ± 4.5 75.0 ± 2.4 12.1 ± 1.5 600 55.0 ± 9.1 1.3 ± 4.0 79.6 ± 4.9 19.3 ± 6.5 650 46.3 ± 4.2 -3.1 ± 1.2 76.5 ± 1.8 14.8 ± 2.4 700 49.0 ± 9.8 -2.3 ± 3.7 73.6 ± 3.6 10.9 ± 2.4 750 41.4 ± 3.5 -4.7 ± 1.6 74.3 ± 3.9 11.1 ± 3.4 800 55.6 ± 6.3 0.3 ± 2.6 75.6 ± 0.9 17.7 ± 3.2 850 56.0 ± 11.2 4.0 ± 5.4 74.9 ± 3.5 14.3 ± 2.5 900 45.3 ± 11.5 -1.6 ± 4.6 80.9 ± 4.9 19.6 ± 3.9 950 42.0 ± 5.9 -4.2 ± 2.1 75.4 ± 3.2 14.3 ± 3.8 1000 49.7 ± 11.5 -1.0 ± 4.5 77.2 ± 0.7 14.9 ± 3.9 Whole simulation 49.0 ± 9.5 -1.6 ± 4.2 75.6 ± 4.2 13.6 ± 4.5
Antagonist Dataaset Agonist Dataset
Time ( 57.8 ± 5.6 0.9 ± 1.8 76.2 ± 2.8 14.0 ± 2.4 100 54.1 ± 1.7 -0.9 ± 1.0 72.7 ± 3.0 11.2 ± 2.3 150 52.5 ± 9.1 -0.6 ± 3.0 72.4 ± 4.6 9.0 ± 3.0 200 55.9 ± 2.0 0.6 ± 0.2 75.9 ± 0.9 12.5 ± 1.2 250 59.1 ± 2.1 2.0 ± 1.3 75.2 ± 4.8 11.5 ± 3.3 300 52.8 ± 5.3 -0.2 ± 3.5 74.7 ± 7.3 13.0 ± 5.6 350 48.6 ± 6.8 -2.3 ± 2.5 70.6 ± 1.3 9.7 ± 1.7 400 52.5 ± 1.1 -0.9 ± 0.5 72.9 ± 2.7 9.5 ± 1.3 450 52.9 ± 7.0 -0.3 ± 3.0 73.8 ± 0.5 10.5 ± 1.0 500 52.7 ± 2.0 -1.4 ± 0.6 70.6 ± 1.8 9.2 ± 0.7 550 54.0 ± 4.7 0.6 ± 3.2 75.3 ± 3.0 11.6 ± 2.0 600 52.7 ± 7.4 -0.3 ± 2.8 69.4 ± 2.0 9.2 ± 1.7 650 55.6 ± 5.9 0.2 ± 2.1 71.5 ± 4.5 8.7 ± 3.5 700 54.6 ± 4.0 0.8 ± 1.3 71.9 ± 4.7 9.9 ± 3.4 750 56.7 ± 1.3 1.5 ± 0.4 70.0 ± 2.2 10.0 ± 0.3 800 59.8 ± 5.0 2.1 ± 2.4 69.5 ± 4.3 8.3 ± 2.6 850 58.1 ± 1.6 1.2 ± 0.9 74.9 ± 0.7 11.4 ± 1.1 900 55.8 ± 3.5 0.4 ± 1.7 70.2 ± 3.7 7.8 ± 2.2 950 53.8 ± 3.9 0.2 ± 2.2 72.5 ± 3.5 10.5 ± 2.1 1000 63.8 ± 7.6 4.6 ± 2.9 68.8 ± 3.0 8.4 ± 2.3 Whole simulation 54.9 ± 6.1 0.3 ± 2.5 72.8 ± 4.4 10.5 ± 3.1 Tables S4. ROC AUC and adjusted log AUC values for virtual screenings using only active ligands (for the antagonist dataset the agonist ligands were considered as the only inactives and vice versa). Decoy molecules were excluded from calculations. 
A) Crystal structures
